{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:00:00Z","timestamp":1792184400154,"version":"4.4.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41030-026-00370-1","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:01:27Z","timestamp":1782756087000},"page":"763-783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["COPD Biologics: Right Patient, Right Pathway, Right Time"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-9513","authenticated-orcid":false,"given":"Lydia J.","family":"Finney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj K.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"12","key":"370_CR1","doi-asserted-by":"publisher","first-page":"e2346598","DOI":"10.1001\/JAMANETWORKOPEN.2023.46598","volume":"6","author":"E Boers","year":"2023","unstructured":"Boers E, Barrett M, Su JG, Benjafield AV, Sinha S, Kaye L, et al. Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open. 2023;6(12):e2346598. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2023.46598.","journal-title":"JAMA Netw Open"},{"key":"370_CR2","unstructured":"2026 GOLD Report and Pocket Guide\u2014Global Initiative for Chronic Obstructive Lung Disease\u2014GOLD [Internet]. [cited 2026 Apr 28]. Available from: https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/."},{"key":"370_CR3","doi-asserted-by":"publisher","unstructured":"Finney LJ, MacLeod M, Wedzicha JA. New insights into the pathophysiology and epidemiology of COPD exacerbations. In: COPD in the 21st century. 2024. https:\/\/doi.org\/10.1183\/2312508x.10007923.","DOI":"10.1183\/2312508x.10007923"},{"issue":"3","key":"370_CR4","doi-asserted-by":"publisher","first-page":"L253","DOI":"10.1152\/ajplung.00292.2025","volume":"330","author":"V Ho","year":"2026","unstructured":"Ho V, Baker JR, Fenwick PS, Willison KR, Klug DR, Barnes PJ, et al. Single-cell microfluidic quantification of miRNA-21 and miRNA-34a reveals miRNA interactions in small airway epithelial cells and fibroblasts from patients with COPD. Am J Physiol Lung Cell Mol Physiol. 2026;330(3):L253\u201365. https:\/\/doi.org\/10.1152\/ajplung.00292.2025.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"370_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1165\/rcmb.2024-0183OC","volume":"73","author":"JV Devulder","year":"2025","unstructured":"Devulder JV, Baker JR, Fenwick PS, Odqvist L, Donnelly LE, Barnes PJ. Chronic obstructive pulmonary disease airway epithelial cell-derived extracellular vesicles spread cellular senescence via microRNA-34a. Am J Respir Cell Mol Biol. 2025;73(2):210\u201320. https:\/\/doi.org\/10.1165\/rcmb.2024-0183OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"370_CR6","doi-asserted-by":"publisher","first-page":"L266","DOI":"10.1152\/AJPLUNG.00419.2022","volume":"326","author":"CL Wrench","year":"2024","unstructured":"Wrench CL, Baker JR, Monkley S, Fenwick PS, Murray L, Donnelly LE, et al. Small airway fibroblasts from patients with chronic obstructive pulmonary disease exhibit cellular senescence. Am J Physiol Lung Cell Mol Physiol. 2024;326(3):L266\u201379. https:\/\/doi.org\/10.1152\/AJPLUNG.00419.2022.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"370_CR7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1095OC","author":"LJ Finney","year":"2019","unstructured":"Finney LJ, Belchamber KBR, Fenwick PS, Kemp SV, Edwards MR, Mallia P, et al. Human rhinovirus impairs the innate immune response to bacteria in alveolar macrophages in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019. https:\/\/doi.org\/10.1164\/rccm.201806-1095OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"370_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2466-14-112","volume":"14","author":"O Eltboli","year":"2014","unstructured":"Eltboli O, Bafadhel M, Hollins F, Wright A, Hargadon B, Kulkarni N, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014;14(1):112. https:\/\/doi.org\/10.1186\/1471-2466-14-112.","journal-title":"BMC Pulm Med"},{"issue":"9","key":"370_CR9","doi-asserted-by":"publisher","first-page":"e0163139","DOI":"10.1371\/journal.pone.0163139","volume":"11","author":"MA Bewley","year":"2016","unstructured":"Bewley MA, Belchamber KBR, Chana KK, Budd RC, Donaldson G, Wedzicha JA, et al. Differential effects of p38, MAPK, PI3K or rho kinase inhibitors on bacterial phagocytosis and efferocytosis by macrophages in COPD. PLoS ONE. 2016;11(9):e0163139. https:\/\/doi.org\/10.1371\/journal.pone.0163139.","journal-title":"PLoS ONE"},{"key":"370_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-024-50197-0","author":"O Katsoulis","year":"2024","unstructured":"Katsoulis O, Toussaint M, Jackson MM, Mallia P, Footitt J, Mincham KT, et al. Neutrophil extracellular traps promote immunopathogenesis of virus-induced COPD exacerbations. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/S41467-024-50197-0.","journal-title":"Nat Commun"},{"key":"370_CR11","doi-asserted-by":"publisher","unstructured":"Wright TK, Gibson PG, Simpson JL, McDonald VM, Wood LG, Baines KJ. Neutrophil extracellular traps are associated with infl ammation in chronic airwaydisease. Respirology. 2016;21:467\u2013475. https:\/\/doi.org\/10.1111\/resp.12730","DOI":"10.1111\/resp.12730"},{"issue":"20","key":"370_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1042\/CS20255452","volume":"139","author":"M Fricker","year":"2025","unstructured":"Fricker M, Lokwani R. COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets. Clin Sci (Lond). 2025;139(20):1199\u2013214. https:\/\/doi.org\/10.1042\/CS20255452.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"370_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1183\/09031936.04.00089004","volume":"23","author":"MWR Pletz","year":"2004","unstructured":"Pletz MWR, Ioanas M, de Roux A, Burkhardt O, Lode H. Reduced spontaneous apoptosis in peripheral blood neutrophils during exacerbation of COPD. Eur Respir J. 2004;23(4):532\u20137. https:\/\/doi.org\/10.1183\/09031936.04.00089004.","journal-title":"Eur Respir J"},{"issue":"9","key":"370_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1164\/RCCM.201008-1285OC","volume":"183","author":"E Sapey","year":"2011","unstructured":"Sapey E, Stockley JA, Greenwood H, Ahmad A, Bayley D, Lord JM, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1176\u201386. https:\/\/doi.org\/10.1164\/RCCM.201008-1285OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"370_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1164\/RCCM.201405-0992OC","volume":"191","author":"SI Rennard","year":"2015","unstructured":"Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(9):1001\u201311. https:\/\/doi.org\/10.1164\/RCCM.201405-0992OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"370_CR16","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1378\/chest.126.3.926","volume":"126","author":"DA Mahler","year":"2004","unstructured":"Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing lnterleukin-8 in COPD: a pilot study. Chest. 2004;126(3):926\u201334. https:\/\/doi.org\/10.1378\/chest.126.3.926.","journal-title":"Chest"},{"issue":"1","key":"370_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/S12931-017-0633-7","volume":"18","author":"PMA Calverley","year":"2017","unstructured":"Calverley PMA, Sethi S, Dawson M, Ward CK, Finch DK, Penney M, et al. A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res. 2017;18(1):153. https:\/\/doi.org\/10.1186\/S12931-017-0633-7.","journal-title":"Respir Res"},{"key":"370_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pupt.2015.01.005","volume":"31","author":"P Rogliani","year":"2015","unstructured":"Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;31:15\u201327. https:\/\/doi.org\/10.1016\/j.pupt.2015.01.005.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"370_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000117386","volume":"76","author":"MA Dentener","year":"2008","unstructured":"Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EFM. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration. 2008;76(3):275\u201382. https:\/\/doi.org\/10.1159\/000117386.","journal-title":"Respiration"},{"issue":"9","key":"370_CR20","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1164\/RCCM.200607-995OC","volume":"175","author":"SI Rennard","year":"2007","unstructured":"Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926\u201334. https:\/\/doi.org\/10.1164\/RCCM.200607-995OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"370_CR21","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/ALL.14661","volume":"76","author":"A Higham","year":"2020","unstructured":"Higham A, Beech A, Wolosianka S, Jackson N, Long G, Kolsum U, et al. Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease. Allergy. 2020;76(6):1861. https:\/\/doi.org\/10.1111\/ALL.14661.","journal-title":"Allergy"},{"issue":"3","key":"370_CR22","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jaci.2024.03.023","volume":"154","author":"M Tang","year":"2024","unstructured":"Tang M, Charbit AR, Johansson MW, Jarjour NN, Denlinger LC, Raymond WW, et al. Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma. J Allergy Clin Immunol. 2024;154(3):580\u2013591.e6. https:\/\/doi.org\/10.1016\/j.jaci.2024.03.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"370_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/CEI\/UXAC038","volume":"209","author":"P Gaur","year":"2022","unstructured":"Gaur P, Zaffran I, George T, Rahimli Alekberli F, Ben-Zimra M, Levi-Schaffer F. The regulatory role of eosinophils in viral, bacterial, and fungal infections. Clin Exp Immunol. 2022;209(1):72\u201382. https:\/\/doi.org\/10.1093\/CEI\/UXAC038.","journal-title":"Clin Exp Immunol"},{"key":"370_CR24","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202407-1287RL","author":"F Baraldi","year":"2025","unstructured":"Baraldi F, Bartlett-Pestle S, Allinson JP, Macleod M, Mah J, Bloom C, et al. Blood eosinophil count stability in chronic obstructive pulmonary disease and the eosinophilic exacerbator phenotype. Am J Respir Crit Care Med. 2025. https:\/\/doi.org\/10.1164\/RCCM.202407-1287RL.","journal-title":"Am J Respir Crit Care Med"},{"key":"370_CR25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01005-2024","author":"AA Diaz","year":"2024","unstructured":"Diaz AA, Grumley S, Yen A, Sonavane S, Elalami R, Abdalla M, et al. Eosinophils, mucus plugs and clinical outcomes: findings from two COPD cohorts. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.01005-2024.","journal-title":"Eur Respir J"},{"issue":"3","key":"370_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/thx.2004.032516","volume":"60","author":"CE Brightling","year":"2005","unstructured":"Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193\u20138. https:\/\/doi.org\/10.1136\/thx.2004.032516.","journal-title":"Thorax"},{"key":"370_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1279-4","author":"GH Long","year":"2020","unstructured":"Long GH, Southworth T, Kolsum U, Donaldson GC, Wedzicha JA, Brightling CE, et al. The stability of blood eosinophils in chronic obstructive pulmonary disease. Respir Res. 2020. https:\/\/doi.org\/10.1186\/s12931-020-1279-4.","journal-title":"Respir Res"},{"key":"370_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207021","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid\/longacting \u03b2-2 agonist efficacy in COPD. Thorax. 2016. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207021.","journal-title":"Thorax"},{"key":"370_CR29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02119-2019","author":"AG Mathioudakis","year":"2020","unstructured":"Mathioudakis AG, Bikov A, Foden P, Lahousse L, Brusselle G, Singh D, et al. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.02119-2019.","journal-title":"Eur Respir J"},{"key":"370_CR30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201509-1869OC","author":"S Vedel-Krogh","year":"2016","unstructured":"Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the copenhagen general population study. Am J Respir Crit Care Med. 2016. https:\/\/doi.org\/10.1164\/rccm.201509-1869OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"370_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.010","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018. https:\/\/doi.org\/10.1016\/j.jaci.2018.04.010.","journal-title":"J Allergy Clin Immunol"},{"key":"370_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01482-1","author":"D Singh","year":"2020","unstructured":"Singh D, Wedzicha JA, Siddiqui S, De La Hoz A, Xue W, Magnussen H, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020. https:\/\/doi.org\/10.1186\/s12931-020-01482-1.","journal-title":"Respir Res"},{"issue":"5","key":"370_CR33","doi-asserted-by":"publisher","first-page":"1900110","DOI":"10.1183\/13993003.00110-2019","volume":"55","author":"P Jogdand","year":"2020","unstructured":"Jogdand P, Siddhuraj P, Mori M, Sanden C, J\u00f6nsson J, Walls AF, et al. Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue. Eur Respir J. 2020;55(5):1900110. https:\/\/doi.org\/10.1183\/13993003.00110-2019.","journal-title":"Eur Respir J"},{"key":"370_CR34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01865-2021","author":"T Al-Shaikhly","year":"2022","unstructured":"Al-Shaikhly T, Murphy RC, Parker A, Lai Y, Altman MC, Larmore M, et al. Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.01865-2021.","journal-title":"Eur Respir J"},{"key":"370_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/all.14016","author":"L George","year":"2020","unstructured":"George L, Taylor AR, Esteve-Codina A, Soler Artigas M, Thun GA, Bates S, et al. Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy. 2020. https:\/\/doi.org\/10.1111\/all.14016.","journal-title":"Allergy"},{"issue":"2","key":"370_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jaci.2023.03.023","volume":"152","author":"WE LeSuer","year":"2023","unstructured":"LeSuer WE, Kienzl M, Ochkur SI, Schicho R, Doyle AD, Wright BL, et al. Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice. J Allergy Clin Immunol. 2023;152(2):469\u2013485.e10. https:\/\/doi.org\/10.1016\/j.jaci.2023.03.023.","journal-title":"J Allergy Clin Immunol"},{"key":"370_CR37","doi-asserted-by":"publisher","first-page":"1700060","DOI":"10.3389\/FALGY.2025.1700060","volume":"6","author":"HK Komori","year":"2025","unstructured":"Komori HK, Ortega H. Potential of alarmin-targeted bispecific and combination therapies in airway disease. Front Allergy. 2025;6:1700060. https:\/\/doi.org\/10.3389\/FALGY.2025.1700060.","journal-title":"Front Allergy"},{"issue":"4","key":"370_CR38","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jaci.2021.10.003","volume":"149","author":"JW Pinkerton","year":"2022","unstructured":"Pinkerton JW, Kim RY, Brown AC, Rae BE, Donovan C, Mayall JR, et al. Relationship between type 2 cytokine and inflammasome responses in obesity-associated asthma. J Allergy Clin Immunol. 2022;149(4):1270\u201380. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.003.","journal-title":"J Allergy Clin Immunol"},{"key":"370_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1445769\/PDF","author":"K Sunata","year":"2024","unstructured":"Sunata K, Miyata J, Kawashima Y, Konno R, Ishikawa M, Hasegawa Y, et al. Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/FIMMU.2024.1445769\/PDF.","journal-title":"Front Immunol"},{"issue":"17","key":"370_CR40","doi-asserted-by":"publisher","first-page":"1817893","DOI":"10.3389\/FIMMU.2026.1817893\/XML","volume":"10","author":"W Ou","year":"2026","unstructured":"Ou W, Wang Y, Hou C, Hou S, Zhou Y, Wang J, et al. Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy. Front Immunol. 2026;10(17):1817893. https:\/\/doi.org\/10.3389\/FIMMU.2026.1817893\/XML.","journal-title":"Front Immunol"},{"issue":"1","key":"370_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/S12931-023-02504-4","volume":"24","author":"K Shen","year":"2023","unstructured":"Shen K, Zhang M, Zhao R, Li Y, Li C, Hou X, et al. Eosinophil extracellular traps in asthma: implications for pathogenesis and therapy. Respir Res. 2023;24(1):231. https:\/\/doi.org\/10.1186\/S12931-023-02504-4.","journal-title":"Respir Res"},{"issue":"9","key":"370_CR42","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.3390\/IJMS27094077","volume":"27","author":"SL Cheng","year":"2026","unstructured":"Cheng SL. Beyond eosinophil depletion: IL-5 as a context-dependent regulator of airway immune networks. Int J Mol Sci. 2026;27(9):4077. https:\/\/doi.org\/10.3390\/IJMS27094077.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"370_CR43","doi-asserted-by":"publisher","first-page":"CD010834","DOI":"10.1002\/14651858.CD010834.PUB4","volume":"2022","author":"HA Farne","year":"2022","unstructured":"Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CVE. Anti\u2010IL\u20105 therapies for asthma. Cochrane Database Syst Rev. 2022;2022(7):CD010834. https:\/\/doi.org\/10.1002\/14651858.CD010834.PUB4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"370_CR44","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/nejme1408614","volume":"371","author":"P Nair","year":"2014","unstructured":"Nair P. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med. 2014;371(13):1249\u201351. https:\/\/doi.org\/10.1056\/nejme1408614.","journal-title":"N Engl J Med"},{"issue":"13","key":"370_CR45","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMOA1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207. https:\/\/doi.org\/10.1056\/NEJMOA1403290.","journal-title":"N Engl J Med"},{"key":"370_CR46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1708208","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMOA1708208.","journal-title":"N Engl J Med"},{"issue":"17","key":"370_CR47","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMOA2413181","volume":"392","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025;392(17):1710\u201320. https:\/\/doi.org\/10.1056\/NEJMOA2413181.","journal-title":"N Engl J Med"},{"issue":"11","key":"370_CR48","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMOA1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023\u201334. https:\/\/doi.org\/10.1056\/NEJMOA1905248.","journal-title":"N Engl J Med"},{"issue":"1","key":"370_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","volume":"13","author":"S Ramakrishnan","year":"2025","unstructured":"Ramakrishnan S, Russell REK, Mahmood HR, Krassowska K, Melhorn J, Mwasuku C, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med. 2025;13(1):59\u201368. https:\/\/doi.org\/10.1016\/S2213-2600(24)00299-6.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"370_CR50","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","volume":"6","author":"RA Panettieri","year":"2018","unstructured":"Panettieri RA, Sj\u00f6bring U, P\u00e9terffy AM, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511\u201325. https:\/\/doi.org\/10.1016\/S2213-2600(18)30184-X.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"370_CR51","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/RCCM.200909-1448OC","volume":"181","author":"J Corren","year":"2010","unstructured":"Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181(8):788\u201396. https:\/\/doi.org\/10.1164\/RCCM.200909-1448OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"370_CR52","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMOA1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMOA1804092.","journal-title":"N Engl J Med"},{"key":"370_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00362-X","author":"M Castro","year":"2025","unstructured":"Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, Gonz\u00e1lez-Barcala FJ, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025. https:\/\/doi.org\/10.1016\/S2213-2600(24)00362-X.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"370_CR54","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/RCCM.202403-0632OC","volume":"211","author":"E Wan","year":"2024","unstructured":"Wan E, Yen A, Elalami R, Grumley S, Nath HP, Wang W, et al. Airway mucus plugs on chest computed tomography are associated with exacerbations in COPD. Am J Respir Crit Care Med. 2024;211(5):814\u201322. https:\/\/doi.org\/10.1164\/RCCM.202403-0632OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"370_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.033","author":"SK Mettler","year":"2024","unstructured":"Mettler SK, Nath HP, Grumley S, Orejas JL, Dolliver WR, Nardelli P, et al. Silent airway mucus plugs in COPD and clinical implications. Chest. 2024. https:\/\/doi.org\/10.1016\/j.chest.2023.11.033.","journal-title":"Chest"},{"key":"370_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2065","author":"AA Diaz","year":"2023","unstructured":"Diaz AA, Orejas JL, Grumley S, Nath HP, Wang W, Dolliver WR, et al. Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease. JAMA. 2023. https:\/\/doi.org\/10.1001\/jama.2023.2065.","journal-title":"JAMA"},{"key":"370_CR57","doi-asserted-by":"publisher","unstructured":"Baraldi F, Mah J, Braddy-Green A, Almuhanna A, Bartlett-Pestell SWJ, Macleod MA, et al. The relationship between eosinophilic activation and mucus plug formation in COPD. Am J Resp Crit Care Med. 2025;211(Abstracts):A2864. https:\/\/doi.org\/10.1164\/ajrccm.2025.211.Abstracts.A2864.","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A2864"},{"issue":"3","key":"370_CR58","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","volume":"128","author":"EM Dunican","year":"2018","unstructured":"Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Investig. 2018;128(3):997\u20131009. https:\/\/doi.org\/10.1172\/JCI95693.","journal-title":"J Clin Investig"},{"key":"370_CR59","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303951","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023. https:\/\/doi.org\/10.1056\/nejmoa2303951.","journal-title":"N Engl J Med"},{"issue":"24","key":"370_CR60","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMOA2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024;390(24):2274\u201383. https:\/\/doi.org\/10.1056\/NEJMOA2401304.","journal-title":"N Engl J Med"},{"issue":"3","key":"370_CR61","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","volume":"13","author":"SP Bhatt","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025;13(3):234\u201343. https:\/\/doi.org\/10.1016\/S2213-2600(24)00409-0.","journal-title":"Lancet Respir Med"},{"key":"370_CR62","unstructured":"Overview | Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils | Guidance | NICE."},{"key":"370_CR63","doi-asserted-by":"publisher","first-page":"100015","DOI":"10.1016\/J.ALLMED.2024.100015","volume":"2","author":"X Shi","year":"2024","unstructured":"Shi X, Tan C, Chen X, Wang W, Xian M, Chen R, et al. Efficacy of dupilumab in the treatment of COPD with type 2 inflammation: a real-world study. Allergy Med. 2024;2:100015. https:\/\/doi.org\/10.1016\/J.ALLMED.2024.100015.","journal-title":"Allergy Med"},{"key":"370_CR64","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2147\/COPD.S525781","volume":"20","author":"O Freund","year":"2025","unstructured":"Freund O, Meoded O, Arnaout T, Friedman Regev I, Kupershmidt A, Enghelberg S, et al. Real-world experience of dupilumab treatment for patients with COPD\u2014a single center prospective study. Int J Chron Obstr Pulm Dis. 2025;20:2753\u201360. https:\/\/doi.org\/10.2147\/COPD.S525781.","journal-title":"Int J Chron Obstr Pulm Dis"},{"key":"370_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155891","author":"C Cayrol","year":"2022","unstructured":"Cayrol C, Girard JP. Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine. 2022. https:\/\/doi.org\/10.1016\/j.cyto.2022.155891.","journal-title":"Cytokine"},{"key":"370_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0003331","author":"C Moussion","year":"2008","unstructured":"Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019? PLoS One. 2008. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0003331.","journal-title":"PLoS One"},{"issue":"4","key":"370_CR67","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.4049\/JIMMUNOL.179.4.2551","volume":"179","author":"AA Chackerian","year":"2007","unstructured":"Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179(4):2551\u20135. https:\/\/doi.org\/10.4049\/JIMMUNOL.179.4.2551.","journal-title":"J Immunol"},{"key":"370_CR68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbrep.2016.02.002","volume":"5","author":"H Hayakawa","year":"2016","unstructured":"Hayakawa H, Hayakawa M, Tominaga SI. Soluble ST2 suppresses the effect of interleukin-33 on lung type 2 innate lymphoid cells. Biochem Biophys Rep. 2016;5:401\u20137. https:\/\/doi.org\/10.1016\/j.bbrep.2016.02.002.","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"370_CR69","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","volume":"31","author":"AU L\u00fcthi","year":"2009","unstructured":"L\u00fcthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84\u201398. https:\/\/doi.org\/10.1016\/j.immuni.2009.05.007.","journal-title":"Immunity"},{"key":"370_CR70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/NCOMMS9327","volume":"14","author":"ES Cohen","year":"2015","unstructured":"Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. 2015;14:6. https:\/\/doi.org\/10.1038\/NCOMMS9327.","journal-title":"Nat Commun"},{"issue":"9","key":"370_CR71","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1172\/JCI65570","volume":"123","author":"DE Byers","year":"2013","unstructured":"Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Investig. 2013;123(9):3967\u201382. https:\/\/doi.org\/10.1172\/JCI65570.","journal-title":"J Clin Investig"},{"issue":"7","key":"370_CR72","doi-asserted-by":"publisher","first-page":"L619","DOI":"10.1152\/AJPLUNG.00305.2014","volume":"308","author":"J Xia","year":"2015","unstructured":"Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L619\u201327. https:\/\/doi.org\/10.1152\/AJPLUNG.00305.2014.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"370_CR73","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jaci.2014.05.011","volume":"134","author":"D Li","year":"2014","unstructured":"Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol. 2014;134(6):1422\u20131432.e11. https:\/\/doi.org\/10.1016\/j.jaci.2014.05.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"370_CR74","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1165\/RCMB.2013-0093OC","volume":"49","author":"IG Luzina","year":"2013","unstructured":"Luzina IG, Kopach P, Lockatell V, Kang PH, Nagarsekar A, Burke AP, et al. Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol. 2013;49(6):999\u20131008. https:\/\/doi.org\/10.1165\/RCMB.2013-0093OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"370_CR75","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2015.02.011","volume":"42","author":"J Kearley","year":"2015","unstructured":"Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity. 2015;42(3):566\u201379. https:\/\/doi.org\/10.1016\/j.immuni.2015.02.011.","journal-title":"Immunity"},{"issue":"1","key":"370_CR76","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/s41467-024-48441-8","volume":"15","author":"JH Park","year":"2024","unstructured":"Park JH, Mortaja M, Son HG, Zhao X, Sloat LM, Azin M, et al. Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression. Nat Commun. 2024;15(1):4099. https:\/\/doi.org\/10.1038\/s41467-024-48441-8.","journal-title":"Nat Commun"},{"issue":"11","key":"370_CR77","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","volume":"9","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288\u201398. https:\/\/doi.org\/10.1016\/S2213-2600(21)00167-3.","journal-title":"Lancet Respir Med"},{"issue":"10543","key":"370_CR78","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(26)00637-9","volume":"407","author":"A Papi","year":"2026","unstructured":"Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, et al. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026;407(10543):2027\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(26)00637-9.","journal-title":"Lancet"},{"key":"370_CR79","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024","author":"D Singh","year":"2025","unstructured":"Singh D, Guller P, Reid F, Doffman S, Sepp\u00e4l\u00e4 U, Psallidas I, et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur Respir J. 2025. https:\/\/doi.org\/10.1183\/13993003.02231-2024.","journal-title":"Eur Respir J"},{"issue":"1","key":"370_CR80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/S41577-022-00735-Y","volume":"23","author":"R Ebina-Shibuya","year":"2022","unstructured":"Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2022;23(1):24. https:\/\/doi.org\/10.1038\/S41577-022-00735-Y.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"370_CR81","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/JEM.20051135","volume":"202","author":"T Ito","year":"2005","unstructured":"Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213. https:\/\/doi.org\/10.1084\/JEM.20051135.","journal-title":"J Exp Med"},{"issue":"170","key":"370_CR82","doi-asserted-by":"publisher","first-page":"170ra16","DOI":"10.1126\/SCITRANSLMED.3005374","volume":"5","author":"BS Kim","year":"2013","unstructured":"Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5(170):170ra16. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3005374.","journal-title":"Sci Transl Med"},{"issue":"1","key":"370_CR83","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/J.JACI.2012.04.019","volume":"130","author":"DR Nagarkar","year":"2012","unstructured":"Nagarkar DR, Poposki JA, Comeau MR, Biyasheva A, Avila PC, Schleimer RP, et al. Airway epithelial cells activate Th2 cytokine production in mast cells via IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol. 2012;130(1):225. https:\/\/doi.org\/10.1016\/J.JACI.2012.04.019.","journal-title":"J Allergy Clin Immunol"},{"key":"370_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAF1938","author":"KM Vannella","year":"2016","unstructured":"Vannella KM, Ramalingam TR, Borthwick LA, Barron L, Hart KM, Thompson RW, et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis. Sci Transl Med. 2016. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAF1938.","journal-title":"Sci Transl Med"},{"key":"370_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/SCIIMMUNOL.AAF8471","author":"EE West","year":"2016","unstructured":"West EE, Spolski R, Kazemian M, Yu ZX, Kemper C, Leonard WJ. A TSLP-complement axis mediates neutrophil killing of methicillin-resistant Staphylococcus aureus. Sci Immunol. 2016. https:\/\/doi.org\/10.1126\/SCIIMMUNOL.AAF8471.","journal-title":"Sci Immunol"},{"issue":"1","key":"370_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/ANTIOX15010071","volume":"15","author":"V Ojha","year":"2026","unstructured":"Ojha V, Tembhre MK, Gupta V. Enhanced alarmin secretion exacerbates neutrophil extracellular trap (NET) formation in active psoriasis: implication of IL-33 and TSLP in driving NET formation, inflammation and oxidative stress in psoriasis. Antioxidants (Basel). 2026;15(1):71. https:\/\/doi.org\/10.3390\/ANTIOX15010071.","journal-title":"Antioxidants (Basel)"},{"key":"370_CR87","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006787","author":"ML Garc\u00eda-Garc\u00eda","year":"2017","unstructured":"Garc\u00eda-Garc\u00eda ML, Calvo C, Moreira A, Ca\u00f1as JA, Pozo F, Sastre B, et al. Thymic stromal lymphopoietin, IL-33, and periostin in hospitalized infants with viral bronchiolitis. Medicine (Baltimore). 2017. https:\/\/doi.org\/10.1097\/MD.0000000000006787.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"370_CR88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/IMM.13741","volume":"176","author":"A Welham","year":"2025","unstructured":"Welham A, Chorvinsky E, Bhattacharya S, Bera BS, Salka K, Weinstock J, et al. High TSLP responses in the human infant airways are associated with pre-activated airway epithelial IFN antiviral immunity. Immunology. 2025;176(1):49\u201358. https:\/\/doi.org\/10.1111\/IMM.13741.","journal-title":"Immunology"},{"issue":"12","key":"370_CR89","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/2211-5463.12746","volume":"9","author":"Q Yu","year":"2019","unstructured":"Yu Q, Li Y, Wang H, Xiong H. TSLP induces a proinflammatory phenotype in circulating innate cells and predicts prognosis in sepsis patients. FEBS Open Bio. 2019;9(12):2137. https:\/\/doi.org\/10.1002\/2211-5463.12746.","journal-title":"FEBS Open Bio"},{"key":"370_CR90","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2643297","author":"M Boita","year":"2016","unstructured":"Boita M, Bucca C, Riva G, Heffler E, Rolla G. Release of type 2 cytokines by epithelial cells of nasal polyps. J Immunol Res. 2016. https:\/\/doi.org\/10.1155\/2016\/2643297.","journal-title":"J Immunol Res"},{"issue":"6","key":"370_CR91","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/EJI.201445021","volume":"45","author":"MK Lay","year":"2015","unstructured":"Lay MK, C\u00e9spedes PF, Palavecino CE, Le\u00f3n MA, D\u00edaz RA, Salazar FJ, et al. Human metapneumovirus infection activates the TSLP pathway that drives excessive pulmonary inflammation and viral replication in mice. Eur J Immunol. 2015;45(6):1680\u201395. https:\/\/doi.org\/10.1002\/EJI.201445021.","journal-title":"Eur J Immunol"},{"key":"370_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/FMED.2022.741989","volume":"25","author":"H Guo-Parke","year":"2022","unstructured":"Guo-Parke H, Linden D, Mousnier A, Scott IC, Killick H, Borthwick LA, et al. Altered differentiation and inflammation profiles contribute to enhanced innate responses in severe COPD epithelium to rhinovirus infection. Front Med (Lausanne). 2022;25:9. https:\/\/doi.org\/10.3389\/FMED.2022.741989.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"370_CR93","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000329131","volume":"4","author":"J Calv\u00e9n","year":"2012","unstructured":"Calv\u00e9n J, Yudina Y, Hallgren O, Westergren-Thorsson G, Davies DE, Brandelius A, et al. Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases. J Innate Immun. 2012;4(1):86\u201399. https:\/\/doi.org\/10.1159\/000329131.","journal-title":"J Innate Immun"},{"issue":"19","key":"370_CR94","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMOA2034975;JOURNAL:JOURNAL:NEJMS","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139. https:\/\/doi.org\/10.1056\/NEJMOA2034975;JOURNAL:JOURNAL:NEJMS.","journal-title":"N Engl J Med"},{"issue":"10","key":"370_CR95","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMOA1704064;CTYPE:STRING:JOURNAL","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936\u201346. https:\/\/doi.org\/10.1056\/NEJMOA1704064;CTYPE:STRING:JOURNAL.","journal-title":"N Engl J Med"},{"key":"370_CR96","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDOA2300135","author":"LH Nordenmark","year":"2023","unstructured":"Nordenmark LH, Hellqvist \u00c5, Emson C, Diver S, Porsbjerg C, Griffiths JM, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023. https:\/\/doi.org\/10.1056\/EVIDOA2300135.","journal-title":"NEJM Evid"},{"issue":"5","key":"370_CR97","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","volume":"11","author":"A Menzies-Gow","year":"2023","unstructured":"Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023;11(5):425\u201338. https:\/\/doi.org\/10.1016\/S2213-2600(22)00492-1.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"370_CR98","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/S41030-025-00294-2","volume":"11","author":"ID Pavord","year":"2025","unstructured":"Pavord ID, Brightling CE, Korn S, Martin NL, Ponnarambil SS, Molfino NA, et al. Tezepelumab can restore normal lung function in patients with severe, uncontrolled asthma: pooled results from the PATHWAY and NAVIGATOR studies. Pulm Ther. 2025;11(2):315. https:\/\/doi.org\/10.1007\/S41030-025-00294-2.","journal-title":"Pulm Ther"},{"issue":"1","key":"370_CR99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","volume":"13","author":"D Singh","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, Han MLK, Christenson SA, Drummond MB, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025;13(1):47\u201358. https:\/\/doi.org\/10.1016\/S2213-2600(24)00324-2.","journal-title":"Lancet Respir Med"},{"key":"370_CR100","unstructured":"Study Details | NCT06878261 | A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | ClinicalTrials.gov [Internet]. [cited 2026 Apr 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06878261."},{"issue":"3","key":"370_CR101","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/CPT.70156;PAGE:STRING:ARTICLE\/CHAPTER","volume":"119","author":"D Singh","year":"2025","unstructured":"Singh D, Brickman CM, Lloyd P, Kalra A, Biswas S, Sinha A, et al. Verekitug, a novel antibody antagonist to the TSLP receptor in adults with asthma: a 32-week randomized phase 1b multiple ascending-dose trial. Clin Pharmacol Ther. 2025;119(3):782\u201390. https:\/\/doi.org\/10.1002\/CPT.70156;PAGE:STRING:ARTICLE\/CHAPTER.","journal-title":"Clin Pharmacol Ther"},{"key":"370_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.13864","author":"A Deiteren","year":"2024","unstructured":"Deiteren A, Bontinck L, Conickx G, Vigan M, Dervaux N, Gassiot M, et al. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY\u00ae compound, in healthy volunteers. Clin Transl Sci. 2024. https:\/\/doi.org\/10.1111\/CTS.13864.","journal-title":"Clin Transl Sci"},{"key":"370_CR103","unstructured":"Press Release: Sanofi\u2019s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP [Internet]. [cited 2026 Apr 20]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2026\/2026-04-07-05-00-00-3268809."},{"issue":"8","key":"370_CR104","doi-asserted-by":"publisher","first-page":"8995","DOI":"10.3390\/CIMB46080532","volume":"46","author":"K Kie\u0142bowski","year":"2024","unstructured":"Kie\u0142bowski K, Sk\u00f3rka P, Plewa P, Bakinowska E, Pawlik A. The role of alarmins in the pathogenesis of atherosclerosis and myocardial infarction. Curr Issues Mol Biol. 2024;46(8):8995. https:\/\/doi.org\/10.3390\/CIMB46080532.","journal-title":"Curr Issues Mol Biol"},{"issue":"3","key":"370_CR105","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5588\/IJTLD.21.0394","volume":"26","author":"BI Awokola","year":"2022","unstructured":"Awokola BI, Amusa GA, Jewell CP, Okello G, Stobrink M, Finney LJ, et al. Chronic obstructive pulmonary disease in sub-Saharan Africa. Int J Tuberc Lung Dis. 2022;26(3):232\u201342. https:\/\/doi.org\/10.5588\/IJTLD.21.0394.","journal-title":"Int J Tuberc Lung Dis"},{"key":"370_CR106","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2147\/COPD.S505016","volume":"20","author":"Q Wang","year":"2025","unstructured":"Wang Q, Wang L, Zhang L, Zhao C, Liu Y, Liu L, et al. Characterizing ECOPD phenotypes: associations with in-hospital outcomes and immunoinflammatory mechanisms. Int J Chron Obstr Pulm Dis. 2025;20:1613. https:\/\/doi.org\/10.2147\/COPD.S505016.","journal-title":"Int J Chron Obstr Pulm Dis"},{"key":"370_CR107","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/COPD.S545837","volume":"20","author":"R Dhar","year":"2025","unstructured":"Dhar R, Ramakrishnan S, Koul PA, Dash M, Patnaik J, Nair S, et al. Blood eosinophil counts in healthy volunteers and in patients with asthma and COPD in India: a multi-centre cross-sectional report. Int J Chron Obstr Pulm Dis. 2025;20:3867\u201375. https:\/\/doi.org\/10.2147\/COPD.S545837.","journal-title":"Int J Chron Obstr Pulm Dis"},{"issue":"suppl 69","key":"370_CR108","doi-asserted-by":"publisher","first-page":"OA2312","DOI":"10.1183\/13993003.CONGRESS-2025.OA2312","volume":"66","author":"MB Long","year":"2025","unstructured":"Long MB, Hull RC, Gilmour A, Viligorska K, Richardson H, New JM, et al. A bispecific monoclonal antibody targeting Pseudomonas aeruginosa in bronchiectasis: results from the GREAT-2 trial. Eur Respir J. 2025;66(suppl 69):OA2312. https:\/\/doi.org\/10.1183\/13993003.CONGRESS-2025.OA2312.","journal-title":"Eur Respir J"},{"issue":"16","key":"370_CR109","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMOA2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025;392(16):1569\u201381. https:\/\/doi.org\/10.1056\/NEJMOA2411664.","journal-title":"N Engl J Med"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00370-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:44:16Z","timestamp":1789116256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00370-1","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lydia. J. Finney Reports Honoraria for educational events or travel to meetings from GSK, AstraZeneca, Sanofi and Roche. Francesca Conway has no conflicts of interest to report. Dheeraj Sethi has no conflicts of interest to report.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}